Effects of the immunosuppressive drug niridazole in isogeneic and allogeneic mouse tumor systems in vivo.
In both isogeneic (Sarcoma 1 in A/JAX mice) and allogeneic (Sarcoma 180 in C57BL/6 mice) mouse tumor systems, treatment of the tumor-bearing mice with niridazole, an antiprarasitic drug, known to be a potent suppressor of cell mediated but not humoral immunity caused enhancement of metastases to regional popliteal nodes. Niridazole also inhibited tumor growth in vivo, as manifested by a significant decrease in the weight of the primary tumors. The enhancement of metastases is attributed to the suppression of cell-mediated immunity by the drug, but the mechanism of tumor-growth inhibition is not yet clear.
D000818:Animals; D007166:Immunosuppressive Agents; D008207:Lymphatic Metastasis; D008297:Male; D051379:Mice; D008805:Mice, Inbred A; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D009560:Niridazole / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D012513:Sarcoma, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D007166:Immunosuppressive Agents; D009560:Niridazole